Innovative Trivalent Nanobody Targeting ALB and IL5 for Advanced Arthritis Therapy

VHH-P453 is a codon-optimized, trivalent humanized nanobody specifically designed to target albumin (ALB) and interleukin 5 (IL5), currently in the biological testing stage of development. With a modular structure incorporating two single-domain antibodies against distinct epitopes of interleukin 5 and a component targeting albumin, VHH-P453 is optimized for both target engagement and extended serum half-life. It is produced using the Pichia pastoris expression system, ensuring efficient manufacturing. This candidate shows significant therapeutic potential for the management of arthritis by leveraging key pathogenic mechanisms mediated by ALB and IL5.

Licensing Opportunity

VHH-P453 is available for out-licensing, with flexible collaboration models to support global development. We welcome inquiries from partners seeking innovative, next-generation nanobody therapeutics for arthritis.

Development Phase

Modality

VHH-P453 is composed of three humanized nanobody domains: two that bind distinct epitopes on IL5 and one that binds ALB. The nanobody format, characterized by its single-domain structure and low molecular weight, endows VHH-P453 with exceptional tissue penetration, robust stability, and favorable pharmacokinetics, particularly relevant for arthritis treatment. The fusion with an ALB-targeting domain further enhances half-life in circulation. Expression in Pichia pastoris supports scalable production and high yield. This architecture is especially advantageous for reaching inflamed arthritic tissues, facilitating effective target engagement and sustained therapeutic action.

Target

ALB is a highly abundant serum protein responsible for maintaining oncotic pressure and serving as a carrier for multiple endogenous and exogenous molecules. IL5 is a cytokine primarily secreted by activated T-cells and plays an integral role in eosinophil activation and survival. ALB is largely expressed in the liver and circulates in plasma, while IL5 is produced by immune cells, notably within inflamed tissues. In the context of arthritis, ALB targeting enables nanobody serum persistence, whereas IL5 is implicated in inflammatory cascades that drive joint pathology. VHH-P453's dual targeting of ALB and IL5 allows for maximized retention in the systemic circulation and direct modulation of inflammatory processes, offering a strategic advantage for arthritis therapy development and competitive differentiation in the market.

Mechanism of Action

VHH-P453 functions via dual mechanisms: selective binding to ALB extends systemic exposure and bioavailability through recycling and reduced renal clearance, while concurrent binding to IL5 disrupts its signal transduction pathways involved in immune cell recruitment and inflammation. This multipronged action effectively modulates aberrant cytokine activity and the persistence of inflammatory cells, central to arthritis pathogenesis. Powered by nanobody technology, VHH-P453’s modular design also supports further engineering, including conjugation or development of bispecific or multispecific biologic formats for expanded and tailored therapeutic applications.

Arthritis

Arthritis encompasses a heterogeneous group of chronic inflammatory disorders that primarily affect the joints, leading to pain, swelling, and progressive loss of function. Prevalent worldwide, arthritis represents a significant cause of disability across all age groups, with diverse subtypes including rheumatoid arthritis and osteoarthritis. Current mainstay treatments involve nonsteroidal anti-inflammatory drugs, corticosteroids, disease-modifying agents, and biologics targeting inflammatory cytokines. However, many patients do not achieve sustained remission or experience adverse effects, underscoring persistent unmet clinical needs. Inflammation-driven joint damage and limited access to personalized therapies remain core challenges. VHH-P453, by targeting both ALB (to optimize pharmacokinetics) and IL5 (to inhibit pivotal inflammatory signals), presents a novel approach with the potential to improve efficacy, patient compliance, and achieve more durable disease control in arthritis.